A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Metastatic or Unresectable Melanoma
Phase of Trial: Phase II/III
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary) ; Relatlimab (Primary)
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 23 Sep 2019 Status changed to recruiting.
- 23 Sep 2019 Planned primary completion date changed from 14 Jul 2020 to 27 Jan 2021.
- 15 Jan 2019 Status changed from recruiting to active, no longer recruiting.